Pharmacokinetic parameters for ganciclovir after treatment with intravenous ganciclovir and oral valganciclovir
. | No. of patients . | Body weight, kg . | AUC0-12, μg/mL · h . | Cmax, μg/mL . | Cmin, μg/mL . | Tmax, h . | t1/2, h . |
|---|---|---|---|---|---|---|---|
| Patients without intestinal GVHD | |||||||
| Oral valganciclovir | 22 | 72.26 ± 11.49 | 53.8 ± 17.97 | 8.8 ± 2.38 | 1.7 ± 0.94 | 2.7 ± 0.75 | 4.2 ± 1.08 |
| Intravenous ganciclovir | 22 | 72.26 ± 11.49 | 39.5 ± 13.91 | 10.3 ± 2.12 | 1.0 ± 0.65 | 1.1 ± 0.64 | 3.4 ± 0.81 |
| Ratio, 90% CI (range) | 22 | 72.26 ± 11.49 | 1.4 (1.2-1.5) | 0.8 (0.8-0.9) | ND | ND | ND |
| P | 22 | 72.26 ± 11.49 | < .001 | .013 | < .001 | < .001 | < .001 |
| Patients with intestinal GVHD I-II | |||||||
| Oral valganciclovir | 5 | 60.22 ± 5.06 | 52.9 ± 21.75 | 8.0 ± 3.25 | 1.9 ± 0.77 | 2.9 ± 0.82 | 6.1 ± 1.92 |
| Intravenous ganciclovir | 5 | 60.22 ± 5.06 | 33.1 ± 12.97 | 10.6 ± 3.30 | 0.7 ± 0.36 | 1.0 ± 0.07 | 3.4 ± 0.74 |
| Ratio, 90% CI (range) | 5 | 60.22 ± 5.06 | 1.6 (1.3-2.0) | 0.7 (0.5-1.0) | ND | ND | ND |
| P | 5 | 60.22 ± 5.06 | .018 | .084 | .016 | .007 | .041 |
| Patient with intestinal GVHD III and severe malabsorption | |||||||
| Oral valganciclovir | 1 | 49.7 | 14.8 | 2.6 | 0.4 | 2.0 | 3.4 |
| Intravenous ganciclovir | 1 | 49.7 | 46.6 | 13.2 | 1.1 | 2.0 | 3.0 |
. | No. of patients . | Body weight, kg . | AUC0-12, μg/mL · h . | Cmax, μg/mL . | Cmin, μg/mL . | Tmax, h . | t1/2, h . |
|---|---|---|---|---|---|---|---|
| Patients without intestinal GVHD | |||||||
| Oral valganciclovir | 22 | 72.26 ± 11.49 | 53.8 ± 17.97 | 8.8 ± 2.38 | 1.7 ± 0.94 | 2.7 ± 0.75 | 4.2 ± 1.08 |
| Intravenous ganciclovir | 22 | 72.26 ± 11.49 | 39.5 ± 13.91 | 10.3 ± 2.12 | 1.0 ± 0.65 | 1.1 ± 0.64 | 3.4 ± 0.81 |
| Ratio, 90% CI (range) | 22 | 72.26 ± 11.49 | 1.4 (1.2-1.5) | 0.8 (0.8-0.9) | ND | ND | ND |
| P | 22 | 72.26 ± 11.49 | < .001 | .013 | < .001 | < .001 | < .001 |
| Patients with intestinal GVHD I-II | |||||||
| Oral valganciclovir | 5 | 60.22 ± 5.06 | 52.9 ± 21.75 | 8.0 ± 3.25 | 1.9 ± 0.77 | 2.9 ± 0.82 | 6.1 ± 1.92 |
| Intravenous ganciclovir | 5 | 60.22 ± 5.06 | 33.1 ± 12.97 | 10.6 ± 3.30 | 0.7 ± 0.36 | 1.0 ± 0.07 | 3.4 ± 0.74 |
| Ratio, 90% CI (range) | 5 | 60.22 ± 5.06 | 1.6 (1.3-2.0) | 0.7 (0.5-1.0) | ND | ND | ND |
| P | 5 | 60.22 ± 5.06 | .018 | .084 | .016 | .007 | .041 |
| Patient with intestinal GVHD III and severe malabsorption | |||||||
| Oral valganciclovir | 1 | 49.7 | 14.8 | 2.6 | 0.4 | 2.0 | 3.4 |
| Intravenous ganciclovir | 1 | 49.7 | 46.6 | 13.2 | 1.1 | 2.0 | 3.0 |
P values are for paired t tests for difference. All plus/minus values are mean ± SD.
AUC indicates the area under the concentration-time curve; Cmax, the maximal concentration; Cmin, the minimum concentration; Tmax, the time to Cmax; t1/2, the half-life of ganciclovir; and ND, not done.